Glenmark Pharma surged 14% after its subsidiary signed a $700 million licensing deal with AbbVie for its experimental cancer drug, ISB 2001. Analysts see up to 29% more upside, with technical experts advising a ‘buy on dips’ strategy. The stock broke out from a key gap zone, and brokerages like Motilal Oswal see targets up to Rs 2,800.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets